Open AccessRational and design of SATRACD study: detecting subclinical anthracycline therapy related cardiac dysfunction in low income country
Author(s) -
Wanzhu Zhang,
Fériel Azibani,
Emmy Okello,
James Kayima,
Victoria Walusansa,
Jackson Orem,
Karen Sliwa
Publication year - 2021
Publication title -
african health sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.391
H-Index - 44
eISSN - 1729-0503
pISSN - 1680-6905
DOI - 10.4314/ahs.v21i2.21
Subject(s) - anthracycline , medicine , subclinical infection , population , intensive care medicine , cancer , cardiology , breast cancer , environmental health
Anthracycline therapy-related cardiac dysfunction (ATRCD) is the most notorious adverse side-effect of chemotherapy. It has become a significant cardiovascular health concern for long-term cancer survivors. With the emerging concept of subclinical ATRCD and newer diagnostictools (Speckle Tracking Echocardiography (STE) and biomarkers), detecting anthracycline cardiac toxicity at an early stage has become an important step to prevent severe cardiac dysfunction and improve the cardiovascular outcome in cancer survivors. Despite the increasing population at risk in sub-Saharan Africa (SSA), there is no contemporary data in Uganda to address the burden, pathogenesis and risk factors of subclinical ATRCD. This big gap in knowledge has led to a lack of local guidelines for monitoring and management of ATRCD.